The Medtronic and Johnson & Johnson-backed epilepsy treatment system provider floated at the top of its range and saw its shares rise 47% on their first day.
NeuroPace, a US-based epilepsy treatment device developer backed by medical device maker Medtronic and pharmaceutical firm Johnson & Johnson, raised $102m yesterday in an initial public offering on the Nasdaq Global Select Market.
The company priced 6 million shares at $17 each, at the upper end of the $15 to $17 range for the offering. They closed on $24.96 on their first day of trading, representing a market capitalisation of approximately $575m.
Founded in 1997, NeuroPace has developed a…
